2018

26/10/2018

Safety and efficacy of a hyaluronic acid derivative in the treatment of vulvovaginal atrophy

Fidia farmaceutici announces the results of a prospective clinical investigation aimed at assessing…
12/06/2018

Fidia Pharma Group has completed the acquisition of Sooft

The acquisition gives an added boost to Fidia’s leadership in the national and international ophthalmology market segment

• Sooft is active in the treatment of all major eye conditions through Sooft, Bioos, Glaucoom, OftaH.T.and Neoox trademarks
• The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 1,100 patents, of which over 700 on hyaluronic acid

Abano Terme (PD), June 11, 2018 – Fidia Pharma Group, an Italian multinational company, leader in…
25/04/2018

New Data Evaluating HYMOVIS® Effects on Cartilage Volume and Type II Collagen Turnover at OARSI World Congress Meeting

Poster Title: “Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee:
Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study”

• Potential beneficial effect of HYMOVIS® on pain and function
• Structural modifying effect in knee OA with HYMOVIS®

Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development…
09/03/2018

FIDIA ANNOUNCES PRESENTATION OF NEW DATA ON A CARTILAGE EXPLANT MODEL AT ORTHOPAEDIC RESEARCH SOCIETY (ORS) ANNUAL MEETING

Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis

“This current study is consistent with the idea that hyaluronic acid therapies for arthritis may act in part through a mechanical pathway that preserves viability of chondrocytes at the cartilage surface,” states Dr. Bonassar.*

Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development…

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Fidia’s other websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Middle East product portfolio focalizes primarily on therapeutic areas such as joint healthcare and tissue repair.

Fidia Pharma Middle East is focused on providing consumers with innovative products that offer quality, safety and performance and exploring innovative channel strategies to access customers and consumers, such as healthcare e-commerce.